SciELO - Scientific Electronic Library Online

 
vol.36 issue3 author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google

Share


Revista chilena de enfermedades respiratorias

On-line version ISSN 0717-7348

Abstract

HERRERA M., Tania; ESCOBAR S., Nadia; RUIZ L., Natalia  and  PENA M., Carlos. Pilot experience with weekly rifapentine-isoniazid treatment for 3 months for latent tuberculosis infection at the Tuberculosis National Program of Chile. Rev. chil. enferm. respir. [online]. 2020, vol.36, n.3, pp.215-222. ISSN 0717-7348.  http://dx.doi.org/10.4067/S0717-73482020000300215.

Introduction:

Prevention of active tuberculosis in risk groups is crucial in tuberculosis control and elimination. Treatment of latent tuberculosis (TITL) with rifapentine and isoniazid in weekly doses for 12 weeks is shorter than other pharmacological treatments, with less liver toxicity, better patient compliance and it is cost-effective. The objective of this study is to evaluate the feasibility to implement this treatment at a programmatic level in Chile.

Methods:

A pilot intervention was conducted in selected territories between May 2018 and March 2019. Within these territories, the regulated treatment with isoniazid 6 months was replaced by the 12 weeks treatment with weekly rifapentine-isoniazide. Additionally, the target population was expanded to include contacts over 14 years old, currently not included in the national guidelines. Treatment consisted in oral administration of rifapentine and isoniazide together once a week for 12 weeks, under supervision of trained health workers.

Results:

From 238 patients entered to the protocol, 53% of them were women and 54.2% were older than 14 years-old. Out of the total number of patients, 203 (85.3%) completed treatment, 22 (9.2%) abandoned, 8 (3.4%) had adverse drug reactions, and 5 ended treatment for different causes.

Conclusion:

Both TITL with rifapentine-isoniazide in 12 supervised weekly doses, and the inclusion of adult contacts in TITL, are feasible to implement at a programmatic level in Chile.

Keywords : Latent tuberculosis; rifapentine; isoniazide; tuberculosis.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )